Patents by Inventor Martin Pomper
Martin Pomper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11871895Abstract: The present invention provides a targeted nanoplex platform for in vivo imaging and theranostic imaging of cancer to simultaneously provide non-invasive assessment of tumor burden and cancer-selective treatments.Type: GrantFiled: November 23, 2016Date of Patent: January 16, 2024Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Ming Li, Ishan Barman, Martin Pomper, Sangeeta Ray
-
Patent number: 11739063Abstract: Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.Type: GrantFiled: February 6, 2019Date of Patent: August 29, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Johns Hopkins UniversityInventors: Jordi Bonaventura, Juan Luis Gomez, Andrew Horti, Feng Hu, Michael Michaelides, Martin Pomper, Marta Sanchez-Soto
-
Publication number: 20230160018Abstract: CKYPB2 induces EMT, sternness, protein synthesis and cell cycle progression through regulation of nucleolin, con-tributing to an increase in tumor growth and metastasis. CKYPB2 can be used as a prognostic marker in African American women with TNBC. CKYPB2 can further select patients with TNBC and ER positive tumors that will likely benefit from inhibitors of ribosomal RNA synthesis, CDK4 and nucleolin.Type: ApplicationFiled: April 16, 2021Publication date: May 25, 2023Inventors: Vanessa Ferreira Merino, Martin Pomper, Saraswati Sukumar
-
Patent number: 11607466Abstract: The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.Type: GrantFiled: December 21, 2017Date of Patent: March 21, 2023Assignee: The Johns Hopkins UniversityInventors: Sridhar Nimmagadda, Martin Pomper, Samit Chatterjee, Wojciech Lesniak, Dhiraj Kumar
-
Publication number: 20210169984Abstract: The present invention relates to methods for sensitizing cancers to death receptor agonist therapies, comprising use of one or more kinase inhibitors. Such kinase inhibitors can be administered and identified as effective for sensitizing to death receptor agonist therapy in vitro or in vivo. Screening for additional kinase inhibitors and other agents that sensitize cancer cells to death receptor agonists is also contemplated, as is preventing and/or treatment of cancer using combination therapies that include such agents (e.g., kinase inhibitor(s) and death receptor agonist(s)). Formulations and kits including such combined agents are also contemplated and described, as are diagnostic/imaging agents that allow for advanced tracking of therapeutic outcome.Type: ApplicationFiled: January 19, 2017Publication date: June 10, 2021Inventors: Seulki Lee, Martin Pomper, Yumin Oh, Magdalena Scully
-
Publication number: 20200399228Abstract: Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.Type: ApplicationFiled: February 6, 2019Publication date: December 24, 2020Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Johns Hopkins UniversityInventors: Jordi Bonaventura, Juan Luis Gomez, Andrew Horti, Feng Hu, Michael Michaelides, Martin Pomper, Marta Sanchez-Soto
-
Publication number: 20190314531Abstract: The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.Type: ApplicationFiled: December 21, 2017Publication date: October 17, 2019Inventors: Sridhar Nimmagadda, Martin Pomper, Samit Chatterjee, Wojciech Lesniak, Dhiraj Kumar
-
Publication number: 20180344164Abstract: The present invention provides a targeted nanoplex platform for in vivo imaging and theranostic imaging of cancer to simultaneously provide non-invasive assessment of tumor burden and cancer-selective treatments.Type: ApplicationFiled: November 23, 2016Publication date: December 6, 2018Inventors: Ming LI, Ishan BARMAN, Martin POMPER, Sangeeta RAY
-
Patent number: 10029023Abstract: The present invention provides targeted nanoplex molecules which carry multimodality imaging reporters together with target enzyme inhibitors such as siRNAs and target prodrug enzymes, that are useful for theranostic imaging of cells and diseases, including, for example, various cancers, and including metastatic prostate cancer. The nanoplex molecules of the present invention provide a platform technology toward many cancer subtypes and alternative therapeutic targets. Downregulation of specific pathways using targeted enzyme inhibitors further provides unique opportunities to target cancer cells selectively while sparing normal tissue. The nanoplex molecule platform described herein has the ability to deliver multiple siRNA enzyme inhibitors. Methods of diagnosis and treatment of various diseases are also included.Type: GrantFiled: March 30, 2012Date of Patent: July 24, 2018Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Martin Pomper, Zaver Bhujwalla, Zhihang Chen, Cong Li, Sridhar Nimmagadda, Marie-France Penet, Sangeeta Ray
-
Publication number: 20170296682Abstract: The presently disclosed subject matter provides non-invasive methods for imaging, quantifying ?7 nicotinic cholinergic receptors, and diagnosing a disease or condition associated with ?7-nAChRs. Methods for preparing radiolabeled derivatives of dibenzothiophene and compounds provided thereof also are provided.Type: ApplicationFiled: May 3, 2017Publication date: October 19, 2017Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Yongjun Gao, Andrew Horti, Robert Dannals, Richard Wahl, Ronnie Mease, Ken Kellar, Paige Finley, Martin Pomper
-
Publication number: 20160235869Abstract: The presently disclosed subject matter provides non-invasive methods for imaging, quantifying ?7 nicotinic cholinergic receptors, and diagnosing a disease or condition associated with ?7-nAChRs. Methods for preparing radiolabeled derivatives of dibenzothiophene and compounds provided thereof also are provided.Type: ApplicationFiled: February 13, 2015Publication date: August 18, 2016Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Yongjun Gao, Andrew Horti, Robert Dannals, Richard Wahl, Ronnie Mease, Ken Kellar, Paige Finley, Martin Pomper
-
Patent number: 9056841Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.Type: GrantFiled: March 19, 2010Date of Patent: June 16, 2015Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Martin Pomper, Ronnie Charles Mease, Ray Sangeeta, Ying Chen
-
Patent number: 8778305Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.Type: GrantFiled: July 31, 2009Date of Patent: July 15, 2014Assignee: The Johns Hopkins UniversityInventors: Martin Pomper, Ronnie Charles Mease, Ying Chen
-
Publication number: 20140178300Abstract: The present invention provides targeted nanoplex molecules which carry multimodality imaging reporters together with target enzyme inhibitors such as siRNAs and target prodrug enzymes, that are useful for theranostic imaging of cells and diseases, including, for example, various cancers, and including metastatic prostate cancer. The nanoplex molecules of the present invention provide a platform technology toward many cancer subtypes and alternative therapeutic targets. Downregulation of specific pathways using targeted enzyme inhibitors further provides unique opportunities to target cancer cells selectively while sparing normal tissue. The nanoplex molecule platform described herein has the ability to deliver multiple siRNA enzyme inhibitors. Methods of diagnosis and treatment of various diseases are also included.Type: ApplicationFiled: March 30, 2012Publication date: June 26, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Martin Pomper, Zaver Bhujwalla, Zhihang Chen, Cong Li, Sridhar Nimmagadda, Marie-France Penet, Sangeeta Ray
-
Publication number: 20120009121Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.Type: ApplicationFiled: March 19, 2010Publication date: January 12, 2012Applicant: The Johns Hopkins UniversityInventors: Martin Pomper, Ronnie Charles Mease, Ray Sangeeta, Ying Chen
-
Publication number: 20110142760Abstract: Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.Type: ApplicationFiled: July 31, 2009Publication date: June 16, 2011Applicant: The Johns Hopkins UniversityInventors: Martin Pomper, Ronnie Charles Mease, Ying Chen
-
Publication number: 20050129610Abstract: The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the a7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express a7-nicotinic cholinergic receptor to which the compounds of the invention have an affinity.Type: ApplicationFiled: June 24, 2004Publication date: June 16, 2005Inventors: Martin Pomper, John Musachio, Hong Fan, Robert Dannals, Catherine Foss, Eifion Phillips, John Gordon, Dennis McCarthy, Richard Keith, Mark Smith, Richard Heys, Peter Dorff